Investigational immunotherapy candidate, VTP-1000, seeks to address significant unmet need in people with celiac disease.An estimated one in 100 ...

In the ongoing phase 1 study, GIM-407 will be administered orally to healthy volunteers to further characterize the safety, tolerability, and pharmacokinetics. Data collected from this study will help ...

Investigational immunotherapy candidate, VTP-1000, seeks to address significant unmet need in people with celiac disease.An estimated one in 100 people globally suffer from celiac disease, for which ...

Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation ("Immusoft"), a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced positive results ...

A team of researchers from City of Hope and The University of Texas M.D. Anderson Cancer Center has reported safety and ...

23, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the first patient ...

Metsera plans to initiate a Phase 2b trial of MET-097 in Q4 2024, with data anticipated in the first half of 2025.

Patients can benefit from clinical trials in gynecologic cancers, and knowing that they can advocate for themselves for ...

The Indian Council of Medical Research (ICMR) has formalised a Memorandum of Agreements (MoAs) with multiple sponsors under ...

Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with ...

Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering clinical-stage oncology company dedicated to transforming the lives of ...